Whittier Trust Co. Sells 2,988 Shares of Johnson & Johnson $JNJ

Whittier Trust Co. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 1st quarter, HoldingsChannel reports. The fund owned 181,167 shares of the company’s stock after selling 2,988 shares during the quarter. Whittier Trust Co.’s holdings in Johnson & Johnson were worth $43,656,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. DGS Capital Management LLC increased its position in shares of Johnson & Johnson by 41.2% in the first quarter. DGS Capital Management LLC now owns 13,631 shares of the company’s stock worth $3,332,000 after purchasing an additional 3,976 shares during the period. Indiana Trust & Investment Management Co grew its stake in Johnson & Johnson by 5.9% during the first quarter. Indiana Trust & Investment Management Co now owns 12,549 shares of the company’s stock worth $3,067,000 after buying an additional 700 shares in the last quarter. Ascentis Independent Advisors increased its holdings in Johnson & Johnson by 57.7% in the 1st quarter. Ascentis Independent Advisors now owns 36,150 shares of the company’s stock valued at $8,837,000 after buying an additional 13,224 shares during the period. Seascape Capital Management acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $229,000. Finally, Argus Investors Counsel Inc. lifted its holdings in shares of Johnson & Johnson by 48.1% during the 1st quarter. Argus Investors Counsel Inc. now owns 3,017 shares of the company’s stock worth $737,000 after acquiring an additional 980 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Barclays upped their target price on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Citigroup upped their price objective on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus raised their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Daiwa Securities Group boosted their target price on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $257.74.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced FDA approval for its dual-energy THERMOCOOL SMARTTOUCH SF platform, a positive catalyst that could support growth in the company’s medtech business and improve investor confidence in its pipeline. Article Title
• Positive Sentiment: The stock had recently been pushing to record highs as analysts raised price targets and investors responded to a higher outlook and pre-earnings optimism, suggesting the long-term setup for JNJ remains constructive. Article Title
• Neutral Sentiment: Commentary this week also highlighted JNJ as a defensive healthcare name with steady cash flow, while other pieces focused on valuation, earnings expectations, and healthcare sector comparisons rather than new company-specific setbacks. Article Title
• Negative Sentiment: Despite the positive product news, some trading-focused coverage noted unusual put option activity after the recent run-up, indicating that a portion of the market is positioning for a possible pullback. Article Title
• Negative Sentiment: One market recap also described JNJ as declining more than the broader market, reinforcing the idea that the stock is pausing after a strong advance rather than reacting to a major fundamental problem. Article Title

Johnson & Johnson Trading Down 1.4%

Shares of NYSE JNJ opened at $263.52 on Thursday. The firm has a 50 day moving average price of $235.85 and a two-hundred day moving average price of $232.52. The stock has a market cap of $634.34 billion, a P/E ratio of 30.46, a price-to-earnings-growth ratio of 2.62 and a beta of 0.24. Johnson & Johnson has a 52-week low of $154.80 and a 52-week high of $269.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the firm posted $2.77 EPS. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Insider Buying and Selling

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.